Keep watching this page as it is constantly updated, u can call me +919323115463 or email me/ask info firstname.lastname@example.org
lot of gaps , broken links, will be plugged soon
Hoechst AG (German pronunciation: [ˈhøːçst]) was a German chemicals then life-sciences company that became Aventis Deutschland after its merger with France’s Rhône-PoulencS.A. in 1999. With the new company’s 2004 merger with Sanofi-Synthélabo, it became a subsidiary of the resulting Sanofi-Aventis pharmaceuticals group
With Dr N J DSOUZA, EX RESEARCH DIRECTOR, HOECHST, ……….. Drug Discovery International Conference 2014, Mumbai at Ramada, powai,, mumbai, India on 12 sept 2014
As a child in Mulund, mumbai, India, in/at Hoechst basic research centre, Dr N J DSOUZA, EX RESEARCH DIRECTOR, HOECHST inspired me , I even went to him to show my thesis..great moments were when they discovered Forskolin
DR BANSI LAL
HEAD RESEARCH, HOECHST RESEARCH CENTRE, MULUND, INDIA
DISCOVERED AT MULUND MUMBAI, HOECHST
Dr B N Ganguly retired from Hoechst and Member Dept of Biotech,delhi.
Vinod Kumar Kansal, President – R & D, Teva API India Ltd
Dr. V. K. Kansal is President of the R&D, TEVA API INDIA LTD, located at Greater Noida.. Before joining TEVA, he was Vice president of R&D, Alembic Limited, Vadodora ( Feb. 2002 to May, 2004), Associate Director, Lupin Laboratory ( 1994-2002) and Group Leader, at ICI and Hoechst Research Center.
OLD AERIAL SHOT OF HOECHST MULUND
I WAS IN HOECHST MARION ROUSSEL, PROCESS DEVELOPMENT LAB , MULUND, MUMBAI, INDIA, 1992-1997 AND REPORTING TO DR RALPH STAPEL, TECH DIRECTOR, see below in centre
DR RALPH STAPEL
The lab was state of art in the country
DR ANIL GHOGARE IN CENTRE……..LOT OF HELP FOR ME DURING PHD WORK
DR BALKRISHNA KUKARNI……..LOT OF HELP FOR ME DURING PHD WORK
Senior Vice President at Kyowa Kirin International plc
MYSELF IN HOECHST
I LIVED IN HOECHST STAFF QUARTERS MULUND MUMBAI INDIA
DR SHIREESH AMBHAIKAR AND DR RAMACHANDRA NAIK
DR CHINTAMANI BAPAT, SCIENTIST
EX PRINCIPAL SCIENTIST, RESEARCH CENTRE
DR KALPANA JOSHI
Chief Consultant at Glenmark Pharmaceuticals Ltd.
MAYANK SHUKLA, EX PLANT MANAGER
Satkar grande Thane India
2nd Feb 2019
The former Hoechst AG and today’sIndustriepark Höchst
hoechst dye works
PUBLICATIONS BY DR SUJATA BHAT, DISCOVERER OF FORSKOLIN
Hoechst Marion Roussel traces its roots to an aniline dye factory begun in 1863 at Höchst am Main, Germany. Venturing into the pharmaceutical industry,
|Company History – Sanofi India Ltd.|
|1956- The Company was incorporated as Hoechst Fedco Pharma Pvt. Ltd. on 31st March. The word `Private’ was deleted on 19th April, 1961 as the Company was deemed to be Public Limited Company under Section 41-A of the Act.- The Company manufacture bulk drugs, drug intermediates, veterinary formulations and pesticides. They established with financial and technical collaboration of Farbwerke Hoechst AG (now Hoechst AG), West Germany, which is one of the largest chemical and pharmaceutical manufacturing groups in the world.- Under the Licence and Technical Collaboration Agreement dated 11th July, made between Hoechst AG and the Company, the Company was inter alia granted the right to use the word `HOECHST’ in its corporate name and the use of the trade marks owned by Hoechst AG in India in respect of various pharmaceutical preparations which would be manufactured and marketed by the Company in India on the terms and conditions mentioned in the said Agreement.
– 10,000 Pref. and 10,000 No. of Equity shares of Rs 100 each issued to promoters. 5000 Pref. and 9,867 No. of Equity shares as Rights in proportion to holdings.
– The Company set up a manufacturing unit at Mulund, for production of basic drugs. In also manufactures intermediates including some of the latest discoveries in the Hoechst Group involving high technology and application of sophisticated modern manufacturing techniques. It also supplies basic drugs to other pharmaceutical companies in India as well as to Europe.
– 28,133 No. of Equity shares issued as Rights.
– 37,800 bonus equity shares issued, propn., 3:5. In June and August, 17,000 No. of Equity shares issued as Rights.
– 57,222 Bonus equity shares issued in the proportion 49:100.
– 1,64,990 Bonus equity shares issued in the proportion 94:100,
– 1,70,256 Bonus equity shares issued in the proportion 1:2.
– The Company set up a manufacturing unit at the Kandla Free Trade Zone to cater to the increasing export market for its products.
– 2,55,384 Bonus equity shares issued in the proportion 1:2.
– The main objects of the public issue was to achieve the voluntary dilution of Hoechst AG’s holding in the Company from 50% to 40% and also to provide the requirements of long term resources for capital expenditure to be incurred on account of normal replacement and renovation of capital assets, continuous modernisation and upgradation programmes to achieve efficiency and use of the lates techniques and methods of manufacture to impart high quality and sophistication to the product range.
– 1,19,538 No. of equity shares issued (Prem. of Rs 100 per share) in July, of which 3,800 shares to business associates and 9,600 shares to employees including working directors) were reserved for preferential allotment. The balance 1,78,138 shares offered for public subscription.
– The Land and building water works, plant and machinery of the Company were revalued as on 31st December.
– A new company under the name Hoechst Nepal Pvt. Ltd., was incorporated as a subsidiary of the Company in February in Nepal.
– A new extension of the Haemaccel plant at Mulund and a multi-purpose fine chemicals plant for bulk drugs at Ankleshwar went into commercial production.
– During the year, an industrial licence was obtained for the manufacture of Petoxifylline (TRENTAL), 2 tonnes of Ciclopiroxolamine (BATRAFEN), an antifungal drug and 5.30 lakhs TPA of diagnostic reagents at Ankleshwar.
– Industrial licence was, received for the manufacture of 2 lakh doses of purified chick embroy cell culture vaccine (Human rabies vaccine) known as RABIPUR.
– The Company obtained Central Government approval under the M.R.T.P. Act, 1969 to the establishment of a new undertaking for producing, processing and selling hybrid and high – yielding varieties of seeds.
– The Company issued 2,30,000 – 14% secured redeemable non-convertible debentures of Rs 100 each on private placement basis. These are redeemable at a premium of Rs 5 per debenture on 1st February, 1996.
– The Company re-entered the antifugual market with the introduction of “BATRAFEN” which was an original research product of the Company’s collaborators Hoechst AG, West Germany.
– The Company introduced a new insecticide “HOSTATHION”. “FLAVOMYCIN”, a modern performance promoter for poultry was launched during the year.
– The Pharma formulation plant was commissioned at Ankleshwar in October, liquid injectible automatic filling line was commissioned in Mulund in September.
– New pharma products introduced were TARIVID (a modern oral antibacterial), AVIL retard (sustained release formulation for treatment of allergies) and TABLON (a formulation containing Ibuprofen for the treatment of pain).
– In co-operation with Boots Pharmaceuticals Ltd., a new anti-arthritic drug `FLUROFEN’ was introduced.
– A letter of intent were received for BARALGAN Ketone and fomulations, Glybenclamide and formulations, Hostathion technical and formulations, Fenbendazole substance and formulations and Ethion technical and formulations at the Company’s works in Ankleshwar. Industrial license was received for manufacture of LASIX retard besides receiving endorsement for manufacture of 13 tonnes of AVIL maleate.
– A new herbicide Klass (Diuron) was introduced during the year. `Butox’ and `Tolzan’ were the new products introduced for external and internal parasites.
– Industrial licences were received for manufacture of Tonophosphan, Berenil and Fenbendazole and their formulations at Ankleshwar. Letters of intent were received for manufacture of Novalgin tablets and Roxatidine and their formulations at Ankleshwar and Lasiride and Betrafen and their formulations at Mulund.
– The Company revalued its free-hold land, buildings etc and the net surplus of Rs 470,733,868 arising out of its was transferred partly to capital reserve (Rs 149,489,737) and to Revaluation reserve (Rs 321,244,131).
– A modern anti hypertensive `Rene Dil’ and latest anti-ulcer drug. `Rotane’ were introduced during the year.
– Industrial licences were received for manufacture of Baralgan, Glybenclamide, and their formulations, Roxatidine, Lasiride and formulations and Novalgin tablets at Ankleshwar and Batrafen formulations at Mulund.
– Letters of intent were received for manufacture of Ranipril and formulations, Tabalon tablets and Tarivid tablets at Ankleshwar and cosavil syrup and Streptase formulations at Mulund.
– An additional super centrifuge and auxilliary equipments for the PCEC plant in Ankleshwar were installed and commissioned.
– 19,38,411 No. of Equity shares of Rs 10 each issued at a premium of Rs 60 per share to Hoechst AG to raise its capital from 40% to 51%.
– A product cardare, an ACE inhibitor was introduced. An oral typhoid vaccine called typhonal was also introduced. Candur-R, and antirabies vaccine was launched during the year.
– With effect from 1st April, the Scheme of Arrangement was sanctioned for transfer of the company’s agrochemicals division to Hoechst Schering Agrofoo Ltd. In terms of the scheme every shareholder of the Company holding 50 shares, were allotted 10 shares of Rs 10 each of Hoechst Schering Agrofoo Ltd. without any payment.
– Roussel India, Ltd. in which the Company held 4,18,560 No. of equity shares out of 6,27,840 No. of equity shares of Rs 100 each issued is a subsidiary of the Company.
– 115,15,311 shares issued at a bonus shares in proportion 1:1.
– The new products such as ACE inhibitor, Cardace etc. was attributed. The Company launched INSUMAN (human insulin) apart from Floxidin a new broad spectrum antibiotic. Due to the technical difficulties, the Company had to close both foot and mouth disease vaccine and Candur DHL plants.
– Roussel India Ltd., the Company’s subsidiary was amalgamated with the Company. Accordingly the name of the Company was changed to Hoechst Marion Roussel Ltd., effective 1st January, 1996.
– `Insuman’ an anti-diabetic drug was launched. The production of `Baralgan’ was suspended as per the Govt. order.
– The capacity of Rabipur plant at Ankleshwar was expanded from 1.8 million doses to 3.5 million doses per annum to meet the increased demand for the product.
– The Company proposed to set up a joint venture company with Chiron Corporation, USA for manufacture of vaccines of Chiron group. The company proposed to take up 49% of the share capital of the said company.
– The Company proposed to introduce four new products viz. Frisium (anti-epileptic). Amaryl (oran anti-diabetic) cefrom (4th generation cephalosporin) and Targocil (Glycopeptide)
– The German drug multinational Hoechst Roussel is buying out the equity stakes of Colour Chem and two individual entrepreneurs in its Indian joint venture, Hoechst Roussel Vet Private Limited, to convert it into a fully-owned subsidiary.
– Currently, Hoechst Roussel Vet GmbH, along with its subsidiary Hoechst Schering Agrevo Ltd, holds 51 per cent equity in the joint venture.
– Hoechst-Huabei Pharmaceuticals Co. Ltd, is a 50:50 greenfield joint venture between Hoechst Marion Roussel and North china Pharmaceutical Group Corporation (NCPC).
– Hoechst Marion Roussel recently forged a manufacturing joint venture for vaccines with the Chiron group in India.
– Hoechst Marion Roussel (HMR), a 51 per cent subsidiary of Hoechst Marion Roussel, Germany, has a significant presence in pharmaceutical and agrochemicals industries.
– The new joint venture company will manufacture the anti rabies vaccine Rabipur and other vaccines of the Chiron Group.
– HMRL had purchased the 33.33 per cent shareholding of Roussel Laboratories UK in Roussel India, to make the latter a 100 per cent subsidiary of HMRL.
– The company is all set to transfer its animal healthcare business to a joint venture company, in which HMR will have a 49 per cent stake and Chiron Corporation of the US 51 per cent.
– Hoechst proposes to enter into a joint venture with Chiron Corporation of USA for the manufacture of vaccines.
– Hoechst Marion Roussel has launched a voluntary retirement scheme (VRS) at its Mulund factory in Mumbai.
– The Company plans to introduce variants of brands like Allegra and Tavanic in the domestic market.
– The Company has re-designated Ramesh Subrahmanian as deputy managing director of the company with effect from 1st July.
– The Company and Rhone-Poulenc Rorer (India) Ltd. two separate Indian subsidiaries of the French Pharmaceuticals and Chemicals major, Aventis SA, are implementing employee stock option schemes as part of the parent company’s worldwide strategy.
– Hoechst Marion Roussel Ltd. will acquire 29,55,608 No. of Equity shares of Rhone-Poulenc Rorer at Rs 15 per share.
– Hoechst Marion Roussel will now be known as Aventis Pharma even as it aims to maintain a leading position within the Indian pharma sector.
-Aventis Pharma Ltd has informed that the Board of Directors of the company has, at its meeting held on October 30, 2002 appointed Mr W Wagner as a Director of the company in the casual vacancy caused by resignation of Mr J Silvestre.
-Bombay High Court sanctions amalgamation of Rhone-Poulenc Rorer with Aventis Pharma Ltd.
-Aventis Pharma increased its sales to Rs.261cr by 16% as against the corresponding period of the previous year.
-Aventis Pharma Ltd has filed a lawsuit against alleging patent infringement on Six Orange Book patent .
-CRISIL withdrew its AAA rating for the Rs.30cr non-convertible Debenture issue of Aventis Pharma Ltd.
-Mr.M.G. Rao and Dr.S Bhattacharya have been appointed as Alternate Directors to Dr.Carlo de Notaristefani and Mr.W.W.Wagner.
-Aventis Pharma has appointed Mr.Ramesh Subramanian, MD as the Vice-president of the Respiratory Sales for North-East and Mid-Atlantic US.
-Aventis Pharma Ltd has informed that the Company had entered into a Joint Venture (JV) Agreement in April 1998 with Chiron Corporation, USA (Chiron) for the manufacture of the anti-rabies vaccine, Rabipur and for the grant of distribution rights in India to the Company for certain Chiron vaccines.
-Aventis Pharma Limited has appointed Mr. Eric Le-Bris as an Additional Director.
-Aventis Pharma Limited has appointed Mr. S.C. Ghoge as Alternate Director to Mr. Eric Le-Bris. Mr. Ghoge being an employee of the Company, has been appointed a Wholetime Director”.
-Mumbai: Aventis Pharma has launched insulin drug Lantus in a prefilled disposable pen called Solostar.
– Aventis Pharma Ltd has informed about the following changes which have taken place in the Board of Directors of the Company:
1. Mr. M. Dargentolle, Chief Financial Officer of the Company who was Alternate Director to Mr. O. Charmeil has been appointed a Director of the Company with effect from July 19, 2010.
2. Mr. J. M. Georges, Director, Industrial Pharma Intercontinental of the sanofi-aventis Group and Mr. F. X. Duhalde, Director – Finance & Administration of the sanofi-aventis Group, have been appointed as Additional Directors of the Company with effect from July 29, 2010.
– Aventis Pharma Limited Acquisition of Nutraceutical Business of Universal Medicare Private Limited
– Sanofi India, in association with HealthCare Global Enterprises Ltd, has launched an exclusive Fun Center for pediatric patients in Bangalore, Karnataka
– Sanofi India launches re-usable insulin pen AllStar for Indian patients
– Sanofi appoints Susheel Umesh as Head of Commercial Operations for its Pharmaceutical Operations in India
-Company has changed its name from Aventis Pharma Ltd. to Sanofi India Ltd.
-Sanofi India launches Combiflam Plus. – Sanofi ties up with IDF, PHFI to fight against diabetes among children in India. -“Sanofi partners with PVR Nest for innovative ‘Healthy Children, happy children initiative”. -“Madhuri Dixit creates signature diabetes dance step for ‘What Step Will you Take Today’, a Sanofi India initiative”. -Sanofi India inks pact with Suzlon Energy for renewable energy.
-Sanofi India – Diabetic Teen from Pune achieves unique feat. -Sanofi partners with Emcure Pharmaceuticals for marketing and distribution of its oncology portfolio in India.
Dr. Neelima Deuskar
Dr.Upendra K Jani
Consultant in Drug Discovery
- +919892410547 (Mobile)
Sr. Business Analyst at NuLEAP Technologies PL
Training in Chemical Process R&D, QbD,
Senior Vice President at Kyowa Kirin International plc
Former Head API (Research) at Rusan Pharma Ltd
Ex-CSO of HIKAL Research Pune
Advisor (R&D) – Strategy, Innovation & Pr
Discovery Engine at Cipla Ltd
Hazrat Sufi Sayyed Mansoorul hasan shah (RA) Bhandup, khindipada, Mumbai
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO …..FOR BLOG HOME CLICK HERE
Join me on Linkedin
Join me on Facebook FACEBOOK
Join me on google plus Googleplus
LIONEL MY SON
He was only in first standard in school when I was hit by a deadly one in a million spine stroke called acute transverse mylitis, it made me 90% paralysed and bound to a wheel chair, Now I keep him as my source of inspiration and helping millions, thanks to millions of my readers who keep me going and help me to keep my son happy